Ironjustic
Wed, Jul-06-05, 06:30
Nonalcoholic fatty liver disease and the metabolic syndrome.
Curr Opin Lipidol. 2005 Aug; 16(4): 421-427 Marchesini G,
Marzocchi R, Agostini F, Bugianesi E
PURPOSE OF REVIEW: Clinical, epidemiological and biochemical
data strongly support the concept that nonalcoholic fatty
liver disease is the hepatic manifestation of the metabolic
syndrome. Insulin resistance is the common factor connecting
obesity, diabetes, hypertension and dyslipidemia with fatty
liver and the progression of hepatic disease to
steatohepatitis, fibrosis, cirrhosis and hepatocellular
carcinoma. RECENT FINDINGS: The association of nonalcoholic
fatty liver disease with the features of the metabolic
syndrome has been confirmed in several epidemiological
studies. The diagnostic and clinical significance of raised
liver enzymes has been questioned; advanced hepatic disease
may also be present in individuals with ultrasonographically
detected steatosis and normal aminotransferase levels. The
role of adipokines (leptin, adiponectin) and cytokines (tumor
necrosis factor-alpha, interleukin-6, transforming growth
factor-beta) in disease progression is probably pivotal,
mediated by oxidative stress. The importance of iron
accumulation in this process has not been confirmed.
Treatments aimed at weight loss remain a primary option; among
pharmacological interventions, insulin sensitizers (glitazones
and metformin) have confirmed beneficial effects on both
biochemical and histological data, but new treatments are on
the horizon. SUMMARY: Nonalcoholic fatty liver disease
prevalence in Western countries is high and there is a trend
towards a further increase, with millions of people at risk of
advanced liver disease. The epidemiological evidence, the
lifestyle origin of the disease and the cost of
pharmacotherapy make prevention a primary goal, and will
contribute to making behavior therapy the background
treatment. We need specific programs and carefully controlled,
randomized studies to tackle simultaneously all the components
of the metabolic syndrome.
Read more <">http://www.hubmed.org/display.cgi?issn=09579672;-
uids=15990591>
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com Man
Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore DEAD
PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
Curr Opin Lipidol. 2005 Aug; 16(4): 421-427 Marchesini G,
Marzocchi R, Agostini F, Bugianesi E
PURPOSE OF REVIEW: Clinical, epidemiological and biochemical
data strongly support the concept that nonalcoholic fatty
liver disease is the hepatic manifestation of the metabolic
syndrome. Insulin resistance is the common factor connecting
obesity, diabetes, hypertension and dyslipidemia with fatty
liver and the progression of hepatic disease to
steatohepatitis, fibrosis, cirrhosis and hepatocellular
carcinoma. RECENT FINDINGS: The association of nonalcoholic
fatty liver disease with the features of the metabolic
syndrome has been confirmed in several epidemiological
studies. The diagnostic and clinical significance of raised
liver enzymes has been questioned; advanced hepatic disease
may also be present in individuals with ultrasonographically
detected steatosis and normal aminotransferase levels. The
role of adipokines (leptin, adiponectin) and cytokines (tumor
necrosis factor-alpha, interleukin-6, transforming growth
factor-beta) in disease progression is probably pivotal,
mediated by oxidative stress. The importance of iron
accumulation in this process has not been confirmed.
Treatments aimed at weight loss remain a primary option; among
pharmacological interventions, insulin sensitizers (glitazones
and metformin) have confirmed beneficial effects on both
biochemical and histological data, but new treatments are on
the horizon. SUMMARY: Nonalcoholic fatty liver disease
prevalence in Western countries is high and there is a trend
towards a further increase, with millions of people at risk of
advanced liver disease. The epidemiological evidence, the
lifestyle origin of the disease and the cost of
pharmacotherapy make prevention a primary goal, and will
contribute to making behavior therapy the background
treatment. We need specific programs and carefully controlled,
randomized studies to tackle simultaneously all the components
of the metabolic syndrome.
Read more <">http://www.hubmed.org/display.cgi?issn=09579672;-
uids=15990591>
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com Man
Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore DEAD
PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking